c met inhibitor amg 337

Drug Overview

AMG 337 is an experimental cancer medicine. It belongs to a modern group of medicines known as Targeted Therapies or “Smart Drugs.” Unlike standard chemotherapy that attacks all fast-growing cells in the body, targeted therapies act like homing missiles. They are designed to seek out and block specific signals that certain cancer cells use to grow and spread.

While AMG 337 showed some early promise in clinical trials, researchers found that it did not work as well as they had hoped, and it caused difficult side effects like severe headaches. Because of this, the active development of this specific drug was halted. However, the information gathered from its clinical trials has helped scientists create newer, more successful treatments.

• Generic Name: AMG 337
• US Brand Names: None (Investigational Agent)
• Drug Class: c-MET Tyrosine Kinase Inhibitor (Targeted Therapy)
• Route of Administration: Oral (taken by mouth as a pill)
• FDA Approval Status: Not FDA Approved. It is strictly an investigational drug, and its major clinical trials have been discontinued.

What Is It and How Does It Work? (Mechanism of Action)

AMG 337 is a Targeted Therapy designed to shut down a specific “growth antenna” on the surface of cancer cells.

To understand how it works, imagine a cell as a machine that needs a signal to start working. On the outside of the cell, there is a receptor (an antenna) called c-MET. In healthy bodies, c-MET waits for a specific chemical messenger called HGF (Hepatocyte Growth Factor) to attach to it. When HGF attaches, the c-MET antenna turns on and tells the cell to grow and divide safely to heal wounds.

However, in some cancers—especially stomach and esophageal cancers—the cancer cells make too many of these c-MET antennas. This is called “MET amplification.” When there are too many antennas, the growth signal gets stuck in the “ON” position.

At the molecular level, AMG 337 works by plugging directly into the c-MET receptor. By blocking this antenna, the drug stops the receptor from activating internal signaling pathways (specifically the PI3K-AKT and RAS-MAPK pathways). Without these vital signals, the cancer cell gets confused, stops dividing, and eventually goes through a natural death process called apoptosis.

FDA Approved Clinical Indications

Because AMG 337 is an experimental drug whose clinical trials were stopped, it does not have any official FDA-approved uses for the general public.

Oncological Uses (Investigational)

• Historically studied for the treatment of advanced stomach (gastric) cancer with MET amplification.
• Historically studied for esophageal and gastroesophageal junction (GEJ) adenocarcinoma.
• Explored in Phase 1 trials for other advanced solid tumors.

Non-Oncological Uses

• There are no FDA-approved or investigational non-oncological uses for this drug.

Dosage and Administration Protocols

Because AMG 337 was strictly an investigational medicine, there is no commercially available prescription dose. The dosing below reflects the protocols used during its Phase 1 and Phase 2 clinical trials before the studies were stopped.

• 
  Renal and Hepatic Insufficiency: Because the drug did not finish its final testing phases, exact dose rules for people with kidney (renal) or liver (hepatic) disease were never finalized. During trials, patients who developed high liver enzymes had their doses temporarily paused or reduced.

Clinical Efficacy and Research Results

Recent oncological reviews (published between 2020 and 2025) frequently look back at the AMG 337 clinical trials to understand how to build better c-MET inhibitors. The main Phase 2 trial for AMG 337 was stopped early because the drug did not shrink tumors as much as doctors expected.

• Response Rates: In the Phase 2 trial for patients with MET-amplified stomach and esophageal cancers, the Objective Response Rate (ORR) was 18%. This means that only 18 out of 100 patients saw their tumors shrink significantly.
• Effects on Disease Progression: For the patients evaluated, the median Progression-Free Survival (the amount of time the cancer stopped growing) was only 3.4 months.
• Survival Rates: The median Overall Survival (OS) for patients on the drug was 7.9 months. Because these numbers were lower than what was seen in the earliest tests, the manufacturer decided to halt further enrollment.

Safety Profile and Side Effects

AMG 337 caused a very specific set of side effects that made it hard for patients to take the drug every day. Because it is not an FDA-approved medication, it does not carry a formal “Black Box Warning.”

Common Side Effects (>10%)

• Headache: This was the most frequent problem, affecting over 60% of patients.
• Gastrointestinal Upset: Nausea (38%), vomiting (38%), and stomach pain.
• Fatigue: Feeling unusually tired and weak.
• Peripheral Edema: Swelling in the hands, lower legs, and feet.
• Decreased Appetite

Serious Adverse Events

• Severe (Grade 3) Headaches: Headaches so intense they interfered with daily life and required the drug to be stopped.
• Hypertension: Dangerously high blood pressure.
• Liver Toxicity: Spikes in liver enzymes, showing stress on the liver.

Management Strategies

• For Headaches: Doctors in the trial prescribed strong pain relievers, but the headaches were often difficult to control. This led researchers to try splitting the dose to twice a day.
• For High Blood Pressure: Patients were closely monitored and given standard blood pressure medications.

Connection to Stem Cell and Regenerative Medicine

The c-MET protein that AMG 337 blocks is actually a very important part of Regenerative Medicine and stem cell biology. In a healthy body, the HGF/c-MET pathway acts as a distress signal. When tissue is damaged (like a cut on your skin or an injured liver), the body uses this pathway to call stem cells to the area so they can regenerate healthy tissue. Because drugs like AMG 337 block this pathway to starve cancer cells, they can accidentally interfere with the body’s natural stem cells, making it harder for normal wounds to heal. Today, scientists are studying this delicate balance to figure out how to stop cancer without hurting the body’s regenerative stem cells.

Patient Management and Practical Recommendations

(Note: Since AMG 337 is largely discontinued, these recommendations apply generally to patients who participated in its trials or are taking similar investigational c-MET inhibitors).

Pre-Treatment Tests to be Performed

• Tumor Genetic Testing: A biopsy must be tested to prove the tumor actually has “MET amplification.” If the tumor doesn’t have this, the drug will not work.
• Baseline Blood Pressure: To make sure the patient’s blood pressure is safe before starting.
• Liver Function Tests (LFTs): To check the health of the liver.

Precautions During Treatment

• Patients had to monitor their blood pressure closely at home.
• Extremely frequent check-ins were needed to monitor headache pain levels before they became severe.

Do’s and Don’ts

• DO tell your doctor immediately if you experience a severe headache that does not go away with normal pain medicine.
• DO keep a daily symptom diary to share with your clinical trial team.
• DON’T take over-the-counter pain medicines without asking your research doctor first, as they might hide a more serious side effect.
• DON’T ignore swelling in your legs or sudden weight gain, as this can be a sign of fluid retention (edema).

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. AMG 337 is an investigational product whose clinical development has been halted; it is not approved by the FDA for the treatment, cure, or prevention of any disease. Treatment protocols, dosages, and side effects vary by individual and by specific clinical trial guidelines. Patients should always consult with their primary oncologist or a qualified healthcare professional regarding diagnosis, treatment options, and the management of medical conditions. Do not disregard professional medical advice or delay in seeking it because of something you have read in this material.